Paradromics' Brain Implant Receives FDA Approval for Speech Restoration Trials
Photo by Natasha Connell on Unsplash
Paradromics received FDA approval for clinical trials of their Connexus brain chip, designed to restore speech for individuals with severe communication disabilities. The Investigational Device Exemption allows Paradromics to begin early-stage human trials of their brain-computer interface, positioning them as a competitor with Neuralink and Synchron in the neurotechnology industry.
Key takeaways
- Neurotechnology company Paradromics has obtained FDA approval to commence clinical trials for its Connexus brain chip, as reported by Medtech Magazine
- The implant aims to synthetically restore speech capabilities for individuals with severe communication disabilities
- The FDA granted Paradromics an Investigational Device Exemption (IDE), enabling the company to initiate a limited, early-stage clinical study of its brain-computer interface (BCI) system
Related Topics
Want coverage like this for your company?
Local & industry wins build trusted proof, SEO/geo signals and prime national editors.
Check fit (2 min)Is this your company?
Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.
Want to turn mentions into momentum? Find your best path with the Fit Checker. Verified profiles receive a free consult.